A prospective study of breast cancer risk in relatives of BRCA1/BRCA2 mutation carriers.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Breast cancer in the era of integrating "Omics" approaches.Oncogenesis · 2022
   Review
2. Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.Genetics in medicine : official journal of the American College of Medical Genetics · 2018
   Article
3. No evidence of excessive cancer screening in female noncarriers fromCurrent oncology (Toronto, Ont.) · 2017
   Article
4. Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.PloS one · 2017
   Article
5. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.Genetics in medicine : official journal of the American College of Medical Genetics · 2016
   Article
6. No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families.Familial cancer · 2016
   Article
7. BRCA1 Circos: a visualisation resource for functional analysis of missense variants.Journal of medical genetics · 2015
   Article
8. Evidence that BRCA1- or BRCA2-associated cancers are not inevitable.Molecular medicine (Cambridge, Mass.) · 2012
   Article
9. Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011
   Article
10. No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.Breast cancer research and treatment · 2011
    Article
11. Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.The Journal of molecular diagnostics : JMD · 2008
    Review
12. Principles of genetic predisposition to malignancies.Hereditary cancer in clinical practice · 2008
    Article
13. Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence.Science progress
    Review

Corrections and comments

• Comment on
  Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.2007

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as